Cash on Hand for Edwards Lifesciences (EW)
According to Edwards Lifesciences's latest reported financial statements, the company's latest reported cash and short-term investments is $4.23B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingCash on HandSwitch metric
Latest period
$4.23B
YoY change
+6.3%
5Y CAGR
+24.7%
Peak year (2025)
$4.23B
Latest annual
$4.23B
Cash on Hand history chart for Edwards Lifesciences (EW) from 1999 to 2025
Cash on Hand history table for Edwards Lifesciences (EW) from 1999 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $4.23B | +6.3% | ||
| 2024 | $3.98B | +143.5% | ||
| 2023 | $1.63B | +34.4% | ||
| 2022 | $1.22B | -17.1% | ||
| 2021 | $1.47B | +4.6% | ||
| 2020 | $1.40B | -7.5% | ||
| 2019 | $1.52B | +58.6% | ||
| 2018 | $956.50M | -28.5% | ||
| 2017 | $1.34B | +5.2% | ||
| 2016 | $1.27B | +3.8% | ||
| 2015 | $1.22B | -14.9% | ||
| 2014 | $1.44B | +53.6% | ||
| 2013 | $936.90M | +79.7% | ||
| 2012 | $521.40M | +15.7% | ||
| 2011 | $450.50M | +13.7% | ||
| 2010 | $396.10M | +18.6% | ||
| 2009 | $334.10M | +47.3% | ||
| 2008 | $226.80M | +18.6% | ||
| 2007 | $191.20M | +4.6% | ||
| 2006 | $182.80M | +2.4% | ||
| 2005 | $178.60M | +265.2% | ||
| 2004 | $48.90M | -20.0% | ||
| 2003 | $61.10M | +78.7% | ||
| 2002 | $34.20M | -28.7% | ||
| 2001 | $48.00M | +71.4% | ||
| 2000 | $28.00M | — | ||
| 1999 | $0 | — |
Cash on Hand values are taken from Edwards Lifesciences's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Edwards Lifesciences (EW) cash and short-term investments totalled $4.23B – grew 6.3% year-over-year.
Across 2020–2025 (5 years), Edwards Lifesciences cash and short-term investments produced a CAGR of +24.7% – sustaining 3 straight years of year-over-year growth.
The dataset's maximum cash and short-term investments sits at $4.23B (2025); the minimum reading of $0 dates to 1999.
Among 8 Healthcare peers, Edwards Lifesciences (EW) ranks 9th; the peer median for cash and short-term investments is $11.85B.
Edwards Lifesciences Cash on Hand by Year
Edwards Lifesciences Cash on Hand 2025: $4.23B
Edwards Lifesciences cash and short-term investments in 2025 was $4.23B, grew 6.3% from 2024. This figure represents the highest annual value in the available history.
Edwards Lifesciences Cash on Hand 2024: $3.98B
Edwards Lifesciences cash and short-term investments in 2024 was $3.98B, surged 143.5% from 2023.
Edwards Lifesciences Cash on Hand 2023: $1.63B
Edwards Lifesciences cash and short-term investments in 2023 was $1.63B, surged 34.4% from 2022.
Edwards Lifesciences Cash on Hand 2022: $1.22B
Edwards Lifesciences cash and short-term investments in 2022 was $1.22B, declined 17.1% below 2021.
Edwards Lifesciences Cash on Hand 2021: $1.47B
Edwards Lifesciences cash and short-term investments in 2021 was $1.47B.
See more financial history for Edwards Lifesciences (EW).
Sector peers — Cash on Hand
Companies in the same sector as Edwards Lifesciences, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Edwards Lifesciences's cash and short-term investments?
- Latest reported cash and short-term investments for Edwards Lifesciences (EW) is $4.23B (period ending December 31, 2025).
How has Edwards Lifesciences cash and short-term investments changed year-over-year?
- Edwards Lifesciences (EW) cash and short-term investments changed +6.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Edwards Lifesciences cash and short-term investments?
- Edwards Lifesciences (EW) cash and short-term investments compound annual growth rate is +24.7% over the most recent 5 years available.
When did Edwards Lifesciences cash and short-term investments hit its highest annual value?
- Edwards Lifesciences cash and short-term investments reached its highest annual value of $4.23B in 2025.
What was Edwards Lifesciences cash and short-term investments in 2024?
- Edwards Lifesciences (EW) cash and short-term investments in 2024 was $3.98B.
What was Edwards Lifesciences cash and short-term investments in 2025?
- Edwards Lifesciences (EW) cash and short-term investments in 2025 was $4.23B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
EW Overview
Company profile, financial tools, and key metrics
EW Revenue Counter
Earns $199.88 every second. See per minute, hour, and day.
EW Earnings Counter
Earns $34.65 per second net profit. See per minute, hour, and day.
EW Economic Scale
Exceeds Fiji's GDP. Compare with world economies.
EW What If Invested
What if you had invested $1,000? See historical returns from any date.
EW How It Makes Money
Discover visual breakdown of $6.30B in revenue — where it comes from and where it goes.
EW Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
EW Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
EW Daily Price Character
Balanced · 50.0% historical win rate (green days). Streaks & record days.
EW Buybacks
0.93% TTM buyback yield. Shareholder yield & SBC comparison.
EW Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.